FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4362545707> ?p ?o ?g. }

• W4362545707 abstract "<div>Abstract<p>ATP-competitive fibroblast growth factor receptor (FGFR) kinase inhibitors, including BGJ398 and Debio 1347, show antitumor activity in patients with intrahepatic cholangiocarcinoma (ICC) harboring activating <i>FGFR2</i> gene fusions. Unfortunately, acquired resistance develops and is often associated with the emergence of secondary <i>FGFR2</i> kinase domain mutations. Here, we report that the irreversible pan-FGFR inhibitor TAS-120 demonstrated efficacy in 4 patients with <i>FGFR</i>2 fusion–positive ICC who developed resistance to BGJ398 or Debio 1347. Examination of serial biopsies, circulating tumor DNA (ctDNA), and patient-derived ICC cells revealed that TAS-120 was active against multiple FGFR2 mutations conferring resistance to BGJ398 or Debio 1347. Functional assessment and modeling the clonal outgrowth of individual resistance mutations from polyclonal cell pools mirrored the resistance profiles observed clinically for each inhibitor. Our findings suggest that strategic sequencing of FGFR inhibitors, guided by serial biopsy and ctDNA analysis, may prolong the duration of benefit from FGFR inhibition in patients with <i>FGFR2</i> fusion–positive ICC.</p>Significance:<p>ATP-competitive FGFR inhibitors (BGJ398, Debio 1347) show efficacy in <i>FGFR2</i>-altered ICC; however, acquired <i>FGFR2</i> kinase domain mutations cause drug resistance and tumor progression. We demonstrate that the irreversible FGFR inhibitor TAS-120 provides clinical benefit in patients with resistance to BGJ398 or Debio 1347 and overcomes several FGFR2 mutations in ICC models.</p><p><i>This article is highlighted in the In This Issue feature, p. 983</i></p></div>" @default.
• W4362545707 created "2023-04-06" @default.
• W4362545707 creator A5001392592 @default.
• W4362545707 creator A5006284011 @default.
• W4362545707 creator A5007399347 @default.
• W4362545707 creator A5012150503 @default.
• W4362545707 creator A5012368861 @default.
• W4362545707 creator A5012704679 @default.
• W4362545707 creator A5019295794 @default.
• W4362545707 creator A5027546748 @default.
• W4362545707 creator A5030161074 @default.
• W4362545707 creator A5030510204 @default.
• W4362545707 creator A5031332948 @default.
• W4362545707 creator A5032708495 @default.
• W4362545707 creator A5036625904 @default.
• W4362545707 creator A5038339239 @default.
• W4362545707 creator A5038972103 @default.
• W4362545707 creator A5043519976 @default.
• W4362545707 creator A5044715414 @default.
• W4362545707 creator A5050393970 @default.
• W4362545707 creator A5053224790 @default.
• W4362545707 creator A5056275493 @default.
• W4362545707 creator A5058709133 @default.
• W4362545707 creator A5060699951 @default.
• W4362545707 creator A5061627885 @default.
• W4362545707 creator A5061829398 @default.
• W4362545707 creator A5063179737 @default.
• W4362545707 creator A5063875415 @default.
• W4362545707 creator A5064011158 @default.
• W4362545707 creator A5064406116 @default.
• W4362545707 creator A5064958509 @default.
• W4362545707 creator A5065435809 @default.
• W4362545707 creator A5067299042 @default.
• W4362545707 creator A5067520942 @default.
• W4362545707 creator A5070093457 @default.
• W4362545707 creator A5074163638 @default.
• W4362545707 creator A5077716142 @default.
• W4362545707 creator A5083248949 @default.
• W4362545707 creator A5087305091 @default.
• W4362545707 creator A5087308492 @default.
• W4362545707 creator A5088566246 @default.
• W4362545707 creator A5088820011 @default.
• W4362545707 creator A5090989020 @default.
• W4362545707 creator A5091239626 @default.
• W4362545707 date "2023-04-03" @default.
• W4362545707 modified "2023-10-17" @default.
• W4362545707 title "Data from TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion–Positive Intrahepatic Cholangiocarcinoma" @default.
• W4362545707 doi "https://doi.org/10.1158/2159-8290.c.6548189.v1" @default.
• W4362545707 hasPublicationYear "2023" @default.
• W4362545707 type Work @default.
• W4362545707 citedByCount "0" @default.
• W4362545707 crossrefType "posted-content" @default.
• W4362545707 hasAuthorship W4362545707A5001392592 @default.
• W4362545707 hasAuthorship W4362545707A5006284011 @default.
• W4362545707 hasAuthorship W4362545707A5007399347 @default.
• W4362545707 hasAuthorship W4362545707A5012150503 @default.
• W4362545707 hasAuthorship W4362545707A5012368861 @default.
• W4362545707 hasAuthorship W4362545707A5012704679 @default.
• W4362545707 hasAuthorship W4362545707A5019295794 @default.
• W4362545707 hasAuthorship W4362545707A5027546748 @default.
• W4362545707 hasAuthorship W4362545707A5030161074 @default.
• W4362545707 hasAuthorship W4362545707A5030510204 @default.
• W4362545707 hasAuthorship W4362545707A5031332948 @default.
• W4362545707 hasAuthorship W4362545707A5032708495 @default.
• W4362545707 hasAuthorship W4362545707A5036625904 @default.
• W4362545707 hasAuthorship W4362545707A5038339239 @default.
• W4362545707 hasAuthorship W4362545707A5038972103 @default.
• W4362545707 hasAuthorship W4362545707A5043519976 @default.
• W4362545707 hasAuthorship W4362545707A5044715414 @default.
• W4362545707 hasAuthorship W4362545707A5050393970 @default.
• W4362545707 hasAuthorship W4362545707A5053224790 @default.
• W4362545707 hasAuthorship W4362545707A5056275493 @default.
• W4362545707 hasAuthorship W4362545707A5058709133 @default.
• W4362545707 hasAuthorship W4362545707A5060699951 @default.
• W4362545707 hasAuthorship W4362545707A5061627885 @default.
• W4362545707 hasAuthorship W4362545707A5061829398 @default.
• W4362545707 hasAuthorship W4362545707A5063179737 @default.
• W4362545707 hasAuthorship W4362545707A5063875415 @default.
• W4362545707 hasAuthorship W4362545707A5064011158 @default.
• W4362545707 hasAuthorship W4362545707A5064406116 @default.
• W4362545707 hasAuthorship W4362545707A5064958509 @default.
• W4362545707 hasAuthorship W4362545707A5065435809 @default.
• W4362545707 hasAuthorship W4362545707A5067299042 @default.
• W4362545707 hasAuthorship W4362545707A5067520942 @default.
• W4362545707 hasAuthorship W4362545707A5070093457 @default.
• W4362545707 hasAuthorship W4362545707A5074163638 @default.
• W4362545707 hasAuthorship W4362545707A5077716142 @default.
• W4362545707 hasAuthorship W4362545707A5083248949 @default.
• W4362545707 hasAuthorship W4362545707A5087305091 @default.
• W4362545707 hasAuthorship W4362545707A5087308492 @default.
• W4362545707 hasAuthorship W4362545707A5088566246 @default.
• W4362545707 hasAuthorship W4362545707A5088820011 @default.
• W4362545707 hasAuthorship W4362545707A5090989020 @default.
• W4362545707 hasAuthorship W4362545707A5091239626 @default.
• W4362545707 hasConcept C104317684 @default.
• W4362545707 hasConcept C126322002 @default.
• W4362545707 hasConcept C143065580 @default.
• W4362545707 hasConcept C170493617 @default.
• W4362545707 hasConcept C184235292 @default.
• W4362545707 hasConcept C32619005 @default.

• next